Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis

被引：5
|
作者：
Perkins, Andrew Charles
Burbury, Kate
Lehmann, Thomas
Ross, David M.
Reiter, Andreas
Gupta, Vikas
Harrison, Claire
Kiladjian, Jean-Jacques
Vannucchi, Alessandro M.
Wondergem, Marielle
Pack, Robert
Wroclawska, Monika
Wilke, Celine
Zhang, Angela
Heidel, Florian H.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-140408
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Safety and Efficacy of Ruxolitinib Retreatment after Treatment Interruption in Patients Enrolled in an Open-Label, Multicenter, Expanded-Access Study in Myelofibrosis
    Gupta, Vikas
    Tavares, Renato S.
    Griesshammer, Martin
    Foltz, Lynda M.
    Raanani, Pia
    Giraldo, Pilar
    Al-Ali, Haifa Kathrin
    Martino, Bruno
    Tannir, Bayane
    Ronco, Julian Perez
    Ghosh, Jagannath
    Vannucchi, Alessandro M.
    BLOOD, 2014, 124 (21)
  • [22] A Phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naive myelofibrosis
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri
    Mohan, Sanjay
    Ansaldo, Karen
    Wang, Xulong
    Chamoun, Kamal
    Prchal, Josef T.
    Tantravahi, Srinivas K.
    CANCER RESEARCH, 2023, 83 (08)
  • [23] A Phase 1, Open-Label, Dose-Escalation Study of Selinexor Plus Ruxolitinib in Patients with Treatment-Naive Myelofibrosis
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri
    Mohan, Sanjay R.
    Ansaldo, Karen
    Wang, Xulong
    Chamoun, Kamal
    Prchal, Josef T.
    Tantravahi, Srinivas K.
    BLOOD, 2022, 140 : 3986 - 3987
  • [24] The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: An open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis
    McMullin M.F.
    Harrison C.N.
    Niederwieser D.
    Demuynck H.
    Jäkel N.
    Gopalakrishna P.
    McQuitty M.
    Stalbovskaya V.
    Recher C.
    Theunissen K.
    Gisslinger H.
    Kiladjian J.-J.
    Al-Ali H.-K.
    Experimental Hematology & Oncology, 4 (1)
  • [25] Efficacy and Safety of Bleselumab in Kidney Transplant Recipients: A Phase 2, Randomized, Open-Label Study.
    Harland, R.
    Klintmalm, G.
    Jensik, S.
    Yang, H.
    Bromberg, J.
    Holman, J.
    Kumar, M. Anil
    Santos, V.
    Larson, T.
    Wang, X.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 447 - 448
  • [26] Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study
    Harland, Robert C.
    Klintmalm, Goran
    Jensik, Stephen
    Yang, Harold
    Bromberg, Jonathan
    Holman, John
    Kumar, Mysore S. A.
    Santos, Vicki
    Larson, Tami J.
    Wang, Xuegong
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 (01) : 159 - 171
  • [27] A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naive myelofibrosis.
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri Renee
    Mohan, Sanjay
    Mazumder, Amitabha
    Chamoun, Kamal
    Karasik, Igor
    Sbar, Eric
    Dugon, Laura
    Tamir, Sharon
    Wang, Xulong
    Prchal, Josef T.
    Tantravahi, Srinivas Kiran
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Results of an open-label study evaluating the safety and efficacy of rivastigmine in patients not responding adequately to Donepezil
    Figiel, G
    Koumaras, B
    Chen, M
    Gunay, I
    Mirski, D
    INTERNATIONAL PSYCHOGERIATRICS, 2005, 17 : 222 - 223
  • [29] ARC-6: A phase Ib/II, open-label, randomized platform study evaluating the efficacy and safety of AB928-based treatment combinations in patients with metastatic castrate resistant prostate cancer
    Subudhi, S. K.
    Wise, D.
    Liu, S. T.
    Chaudhry, A.
    Kim, J.
    Gardner, O.
    Gilbert, H.
    Grady, M.
    Paoloni, M.
    Krishnan, K.
    Carducci, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S545 - S545
  • [30] Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3trial
    Harrison, Claire N.
    Mesa, Ruben
    Talpaz, Moshe
    Al-Ali, Haifa Kathrin
    Xicoy, Blanca
    Passamonti, Francesco
    Palandri, Francesca
    Benevolo, Giulia
    Vannucchi, Alessandro Maria
    Mediavilla, Clemence
    Iurlo, Alessandra
    Kim, Inho
    Rose, Shelonitda
    Brown, Patrick
    Hernandez, Christopher
    Wang, Jia
    Kiladjian, Jean-Jacques
    LANCET HAEMATOLOGY, 2024, 11 (10): : e729 - e740
12345